Australia's Immuron jumps on increased global sales of Travelan drug
** Shares of Immuron IMC.AX rise as much as 22.7% to
A$0.135, set for best day since March 8, if gains hold
** The biopharmaceutical co says global sales of its
gastrointestinal drug Travelan for year till March 2024 were
A$3.6 mln ($2.39 mln), up 154% from pcp
** Stock at its highest level since March 11
** Immuron stock up 42.9% YTD, as of last close
($1 = 1.5088 Australian dollars)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million